Clinical observation of the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced solid tumors.

Abstract

INTRODUCTION:

Programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors are proved to be promising and are applied for the treatment of a variety of solid tumors. This retrospective study evaluated the efficacy of PD-1/PD-L1 inhibitors in patients with advanced solid tumors and explore the effect of clinical characteristics on it.

MATERIALS AND METHODS:

From October 2017 to April 2020, a total of 90 patients from Capital Medical University Affiliated Beijing Friendship Hospital were enrolled.

RESULTS:

At a median follow-up of 10.55 months, objective response was observed in 23 patients and the objective response rate was 25.6%. The median progression-free survival (PFS) was 5.5 months (95% confidence interval [CI], 3.69-7.37). The 6m-PFS was 45.8% and 12m-PFS was 25.1%. The median overall survival (OS) was 16.9 months (95% CI, not reached [NR]-NR). The 12m-OS was 58.1% and 18m-OS was 48.1%.

CONCLUSION:

The efficacy of PD-1/PD-L1 inhibitors in the treatment of advanced solid tumors was comparable to previous studies. ECOG performance status, smoking status, liver metastasis, neutrophil-to-lymphocyte ratio were independently correlated with PFS while liver metastasis and lactate dehydrogenase level were independently correlated with OS.

• Authors: Miao Wang, Hongchao Zhen, Xiaoyue Jiang, Yuting Lu, Yuhan Wei, Jiangtao Jin, Qin Li
• Journal: Immunity, inflammation and disease (Immun Inflamm Dis) Vol. 9 Issue 4 Pg. 1584-1595 (12 2021) ISSN: 2050-4527 [Electronic] England
• PMID: 34407323 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.

Chemical References

• Immune Checkpoint Inhibitors
• Programmed Cell Death 1 Receptor

Topics

• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Humans
• Immune Checkpoint Inhibitors
• Lung Neoplasms (drug therapy)
• Programmed Cell Death 1 Receptor
• Retrospective Studies